Hip Pelvis 2018; 30(4): 197-201
Published online December 31, 2018
https://doi.org/10.5371/hp.2018.30.4.197
© The Korean Hip Society
Correspondence to : Jun-Shik Kim, MD
(https://orcid.org/0000-0003-0340-4169)
The Joint Replacement Center, Ewha Womans University Medical Center, 1071 Anyangcheon-ro, Yangcheon-gu, Seoul 07985, Korea
TEL: +82-2-2650-5905 FAX: +82-2-2650-5905
E-mail: kjsos@ewha.ac.kr
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
In Western patient populations, the reported incidence of imaging-demonstrated deep vein thrombosis (DVT) after total hip arthroplasty (THA) is as high as 70% without prophylaxis. The reported rates of symptomatic pulmonary embolism (PE) after THA in recent studies range from 0.6% to 1.5%, and the risk of fatal PE ranges from 0.11% to 0.19% in the absence of prophylaxis. Predisposing factors to DVT in western patients include advanced age, previous venous insufficiency, osteoarthritis, obesity, hyperlipidemia, dietary and genetic factors. However, Asian patients who have undergone THA have a strikingly low prevalence of DVT and virtually no postoperative PE. Some authors suggest low clinical prothrombotic risk factors and the absence of some DVT-related genetic factors in Asian patient populations decrease the risk of DVT, PE or both. In Korea, the prevalence of DVT after THA without thromboprophylaxis have ranges from 6.8% to 43.8%, and asymptomatic PE have ranges from 0% to 12.9%; there have been only two reported cases of fatal PE. Deep-wound infections resulting from postoperative hematomas or prolonged wound drainage have been reported with routine thromboprophylaxis. The prevalence of DVT differs varies based on patient ethnicity. Guidelines for the use of thromboprophylaxis were altered and focus on the potential value of outcomes compared with possible complications (e.g., bleeding).
Keywords Total hip arthroplasty, Deep vein thrombosis, Pulmonary embolism, Prophylaxis, Asians
Deep vein thrombosis (DVT) and pulmonary embolism (PE) are serious complications after total hip arthroplasty (THA). In Western populations, the incidence of DVT after THA is reportedly as high as 70% without prophylaxis1). Recently reported rates of symptomatic PE after THA range from 0.6% to 1.5%, and the risk of fatal PE ranges from 0.1% to 0.19% without prophylaxis23).
Predisposing factors for DVT in Western patients include age over 60 years, previous venous insufficiency, obesity, dehydration, one or more comorbidities, hyperlipidemia, concomitant use of oral contraceptives, cancer, dietary factors, genetic factors and others4,56). On the contrary, Asian patients have a strikingly low prevalence of DVT and virtually no postoperative PE after THA7,8,910). Some authors have suggested that Asian populations have low clinical prothrombotic risk factors for DVT and the absence of some genetic factors involving in DVT9,511).
In Korea, the reported prevalence of DVT after THA without thromboprophylaxis ranges from 6.8% to 43.8%, and PE is reported to occur at rates between 0% and 12.9%-mostly asymptomatic. To date, only two cases of fatal PE have been reported1213). Routine use of thromboprophylaxis with anticoagulants has been associated with an increased rate of complications including deep-wound infection caused by postoperative hematoma or prolonged wound drainage.
This study aimed to explore the difference in DVT incidence rates between Asian and Western populations through a literature review and to identify updates to the guidelines for prevention of venous thromboembolism (VTE) to balance the relationship between prophylactic treatment and adverse drug events.
Many publications have supported the use of prophylactic anticoagulant therapy because a decreased rate of DVT after THA can lower the incidence of PE, mortality and prevalence of postphlebitic syndrome14,1516).
Johnson et al.17) reported a prevalence of symptomatic PE after THA of 8% without thromboprophylaxis; there was a mortality rate of 1% associated with these cases of PE. Interestingly, the prevalence and mortality rates of PE have been reported to gradually decrease over time. Freedman et al.18) and Murray et al.19) reported that the rates of DVT after THA were similar irrespective of whether prophylatic treatment was provided. The prevalence of asympotmatic PE ranged from 12.6% to 18.9% and sympotmatic PE occurred only in 1.9% among patients who underwent THA. The rate of fatal PE ranged between 0% and 0.32% irrespective of prophylactic drug therapy1920).
Asian patients have been reported to have a lower prevalence of DVT and PE after THA compared with Western patients8,10,21,22,2324). In the report by Klatsky et al.9), the prevalence of DVT and PE in Asian populations was estimated at 20% of the Western population.
Woo et al.25) noted that the incidence of PE among the Chinese population in Hong Kong was only 10% of the incidence rate observed within Western populations; those Chinese patients in Hong Kong with PE exhibited symptoms that were milder relative to those observed in Western populations.
In a study on DVT in Korean patients, the prevalence of DVT without thromboprophylaxis ranged from 6.8% to 43.8%, and Yoo et al.13) reported that symptomatic DVT rates were 8% and 20.7% in two different studies, respectively. The rate of asymptomatic PE was 12.9%. Hwang et al.12) and Yoo et al.13) reported a single case of symptomatic PE in each study, respectively. In both cases, the patient died. In the study published by Hwang et al.12), the patient received prophylactic dextran.
Kim et al.7) reported that the low prevalence of DVT and PE is attributable to low prevalence of venous disease, low obesity rate, low prevalence of hyperlipidemia, early postoperative exercise, and thrombosis mostly restricted to the veins of the lower limb. A low incidence of DVT and PE in Asian patients can be explained by variations in lifestyles, diet and genetic factors11,2627).
Westrich et al.5) stated the presence of the
Salvati et al.28) reported that about 50% of patients with VTE after THA had heritable thrombophilia, indicating inherited deficiencies of antithrombin III and protein C or prothrombin gene mutations. Therefore, preoperative tests for these three genetic risk factors may help judge the degree of thromboprophylaxis.
Wåhlander et al.24) screened 1,600 patients and noted a tendency for increased risk of VTE and PE with the presence of a mutation in the prothrombin promoter region and factor V Leiden mutation.
Westrich et al.5) reported that the risk of developing PE reached almost 100% when antithrombin levels were lower than normal and the
Zivelin et al.6) identified that the
According to Balasa et al.26), the
Routine thromboprophylaxis-via administration of antithrombotic agents-may cause surgical wound hematomas, bleeding, skin necrosis, thrombophilia, or bleeding in the gastrointestinal tract or urinary system3,2728).
Parvizi et al.2930) reported that the use of low-dose warfarin or heparin may elevate the average international normalized ratio to 1.5 or higher and increase the risk of wound infections due to postoperative hematomas or prolonged wound drainage. Higher incidences of wound complications (e.g., hematomas or delayed wound drainage) occurred after intravenous administration compared with use of oral antithrombotic agents3132).
Patel et al.33) suggested an association between prolonged wound discharge with infections after THA and each day of prolonged wound drainage increased the risk of wound infection by 42%.
Although it is rare, the use of antithrombotic agents such as low molecular weight heparin can restrict regional anesthesia for prevention of spinal cord compression and paralysis following epidural hematoma or epidural catheterization for management of postoperative regional pain16).
The American College of Chest Physicians (ACCP) published the guidelines for prevention of thrombosis in 1992, and it has since been updated. Thromboprophylaxis is strongly recommended for both THA and TKA in the ACCP guidelines. However, the new ACCP guidelines for prevention of thrombosis (9th edition, released in 2012) has focused on preventing symptomatic DVT and PE, and has restricted the use of prophylaxis in patients at a high risk of bleeding34).
In Journal of Arthroplasty in 2005, Callaghan et al.35) opined whether recommendations from the ACCP are appropriate for orthopaedic surgery. Since then, the American Association of Orthopaedic Surgeons (AAOS) developed its own thromboprophylaxis guidelines appropriate for orthopaedic surgery in 2007; an updated version published in 2011 consists of 10 recommendations classified as strong, moderate, weak, inconclusive and consensus based on the levels of evidence3536).
Considering the difference in prevalence of DVT and PE in Korean patients and adverse effects of anticoagulant drugs, the Korean Hip Society generated guidelines in 2011 for the use of DVT prophylaxis for both THA and hip fracture surgery according to DVT and bleeding risk factors4).
General recommendations are as follows:
In cases of delayed surgery, the concurrent use of drug therapy and physical prophylaxis before surgery is strongly recommended in hip fracture patients at high risk of VTE in our aging society.
DVT and PE-potential complications following THA-can be life-threatening, but fortunately, the reported prevalences of DVT and PE are low in Asians and Koreans because of relatively low obesity rates and serum lipid levels, and differences in ethnicity related genetic factors.
Considering complications of routine thromboprophylaxis (e.g., bleeding, hematoma, skin necrosis and infections), it would be more reasonable to use thromboprophylaxis depending on the individual needs of a patient (e.g., medical history and conditions), rather than following the guidelines for Western patients.
Anticoagulants for thromboprophylaxis cannot be easily used in many artificial joint patients who may experience complications due to routine use of thromboprophylaxis with anticoagulants, although not required, but only to avoid uncommon fatal PE.
Fortunately, the recommendations for VTE prophylaxis have been updated and the VTE prevention guidelines recommended by the Korea Hip Society are expected to serve as guidance for the appropriate treatment of Asian populations including Koreans.
Hip Pelvis 2018; 30(4): 197-201
Published online December 31, 2018 https://doi.org/10.5371/hp.2018.30.4.197
Copyright © The Korean Hip Society.
The Joint Replacement Center, Ewha Womans University Medical Center, Seoul, Korea
Correspondence to:Jun-Shik Kim, MD
(https://orcid.org/0000-0003-0340-4169)
The Joint Replacement Center, Ewha Womans University Medical Center, 1071 Anyangcheon-ro, Yangcheon-gu, Seoul 07985, Korea
TEL: +82-2-2650-5905 FAX: +82-2-2650-5905
E-mail: kjsos@ewha.ac.kr
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
In Western patient populations, the reported incidence of imaging-demonstrated deep vein thrombosis (DVT) after total hip arthroplasty (THA) is as high as 70% without prophylaxis. The reported rates of symptomatic pulmonary embolism (PE) after THA in recent studies range from 0.6% to 1.5%, and the risk of fatal PE ranges from 0.11% to 0.19% in the absence of prophylaxis. Predisposing factors to DVT in western patients include advanced age, previous venous insufficiency, osteoarthritis, obesity, hyperlipidemia, dietary and genetic factors. However, Asian patients who have undergone THA have a strikingly low prevalence of DVT and virtually no postoperative PE. Some authors suggest low clinical prothrombotic risk factors and the absence of some DVT-related genetic factors in Asian patient populations decrease the risk of DVT, PE or both. In Korea, the prevalence of DVT after THA without thromboprophylaxis have ranges from 6.8% to 43.8%, and asymptomatic PE have ranges from 0% to 12.9%; there have been only two reported cases of fatal PE. Deep-wound infections resulting from postoperative hematomas or prolonged wound drainage have been reported with routine thromboprophylaxis. The prevalence of DVT differs varies based on patient ethnicity. Guidelines for the use of thromboprophylaxis were altered and focus on the potential value of outcomes compared with possible complications (e.g., bleeding).
Keywords: Total hip arthroplasty, Deep vein thrombosis, Pulmonary embolism, Prophylaxis, Asians
Deep vein thrombosis (DVT) and pulmonary embolism (PE) are serious complications after total hip arthroplasty (THA). In Western populations, the incidence of DVT after THA is reportedly as high as 70% without prophylaxis1). Recently reported rates of symptomatic PE after THA range from 0.6% to 1.5%, and the risk of fatal PE ranges from 0.1% to 0.19% without prophylaxis23).
Predisposing factors for DVT in Western patients include age over 60 years, previous venous insufficiency, obesity, dehydration, one or more comorbidities, hyperlipidemia, concomitant use of oral contraceptives, cancer, dietary factors, genetic factors and others4,56). On the contrary, Asian patients have a strikingly low prevalence of DVT and virtually no postoperative PE after THA7,8,910). Some authors have suggested that Asian populations have low clinical prothrombotic risk factors for DVT and the absence of some genetic factors involving in DVT9,511).
In Korea, the reported prevalence of DVT after THA without thromboprophylaxis ranges from 6.8% to 43.8%, and PE is reported to occur at rates between 0% and 12.9%-mostly asymptomatic. To date, only two cases of fatal PE have been reported1213). Routine use of thromboprophylaxis with anticoagulants has been associated with an increased rate of complications including deep-wound infection caused by postoperative hematoma or prolonged wound drainage.
This study aimed to explore the difference in DVT incidence rates between Asian and Western populations through a literature review and to identify updates to the guidelines for prevention of venous thromboembolism (VTE) to balance the relationship between prophylactic treatment and adverse drug events.
Many publications have supported the use of prophylactic anticoagulant therapy because a decreased rate of DVT after THA can lower the incidence of PE, mortality and prevalence of postphlebitic syndrome14,1516).
Johnson et al.17) reported a prevalence of symptomatic PE after THA of 8% without thromboprophylaxis; there was a mortality rate of 1% associated with these cases of PE. Interestingly, the prevalence and mortality rates of PE have been reported to gradually decrease over time. Freedman et al.18) and Murray et al.19) reported that the rates of DVT after THA were similar irrespective of whether prophylatic treatment was provided. The prevalence of asympotmatic PE ranged from 12.6% to 18.9% and sympotmatic PE occurred only in 1.9% among patients who underwent THA. The rate of fatal PE ranged between 0% and 0.32% irrespective of prophylactic drug therapy1920).
Asian patients have been reported to have a lower prevalence of DVT and PE after THA compared with Western patients8,10,21,22,2324). In the report by Klatsky et al.9), the prevalence of DVT and PE in Asian populations was estimated at 20% of the Western population.
Woo et al.25) noted that the incidence of PE among the Chinese population in Hong Kong was only 10% of the incidence rate observed within Western populations; those Chinese patients in Hong Kong with PE exhibited symptoms that were milder relative to those observed in Western populations.
In a study on DVT in Korean patients, the prevalence of DVT without thromboprophylaxis ranged from 6.8% to 43.8%, and Yoo et al.13) reported that symptomatic DVT rates were 8% and 20.7% in two different studies, respectively. The rate of asymptomatic PE was 12.9%. Hwang et al.12) and Yoo et al.13) reported a single case of symptomatic PE in each study, respectively. In both cases, the patient died. In the study published by Hwang et al.12), the patient received prophylactic dextran.
Kim et al.7) reported that the low prevalence of DVT and PE is attributable to low prevalence of venous disease, low obesity rate, low prevalence of hyperlipidemia, early postoperative exercise, and thrombosis mostly restricted to the veins of the lower limb. A low incidence of DVT and PE in Asian patients can be explained by variations in lifestyles, diet and genetic factors11,2627).
Westrich et al.5) stated the presence of the
Salvati et al.28) reported that about 50% of patients with VTE after THA had heritable thrombophilia, indicating inherited deficiencies of antithrombin III and protein C or prothrombin gene mutations. Therefore, preoperative tests for these three genetic risk factors may help judge the degree of thromboprophylaxis.
Wåhlander et al.24) screened 1,600 patients and noted a tendency for increased risk of VTE and PE with the presence of a mutation in the prothrombin promoter region and factor V Leiden mutation.
Westrich et al.5) reported that the risk of developing PE reached almost 100% when antithrombin levels were lower than normal and the
Zivelin et al.6) identified that the
According to Balasa et al.26), the
Routine thromboprophylaxis-via administration of antithrombotic agents-may cause surgical wound hematomas, bleeding, skin necrosis, thrombophilia, or bleeding in the gastrointestinal tract or urinary system3,2728).
Parvizi et al.2930) reported that the use of low-dose warfarin or heparin may elevate the average international normalized ratio to 1.5 or higher and increase the risk of wound infections due to postoperative hematomas or prolonged wound drainage. Higher incidences of wound complications (e.g., hematomas or delayed wound drainage) occurred after intravenous administration compared with use of oral antithrombotic agents3132).
Patel et al.33) suggested an association between prolonged wound discharge with infections after THA and each day of prolonged wound drainage increased the risk of wound infection by 42%.
Although it is rare, the use of antithrombotic agents such as low molecular weight heparin can restrict regional anesthesia for prevention of spinal cord compression and paralysis following epidural hematoma or epidural catheterization for management of postoperative regional pain16).
The American College of Chest Physicians (ACCP) published the guidelines for prevention of thrombosis in 1992, and it has since been updated. Thromboprophylaxis is strongly recommended for both THA and TKA in the ACCP guidelines. However, the new ACCP guidelines for prevention of thrombosis (9th edition, released in 2012) has focused on preventing symptomatic DVT and PE, and has restricted the use of prophylaxis in patients at a high risk of bleeding34).
In Journal of Arthroplasty in 2005, Callaghan et al.35) opined whether recommendations from the ACCP are appropriate for orthopaedic surgery. Since then, the American Association of Orthopaedic Surgeons (AAOS) developed its own thromboprophylaxis guidelines appropriate for orthopaedic surgery in 2007; an updated version published in 2011 consists of 10 recommendations classified as strong, moderate, weak, inconclusive and consensus based on the levels of evidence3536).
Considering the difference in prevalence of DVT and PE in Korean patients and adverse effects of anticoagulant drugs, the Korean Hip Society generated guidelines in 2011 for the use of DVT prophylaxis for both THA and hip fracture surgery according to DVT and bleeding risk factors4).
General recommendations are as follows:
In cases of delayed surgery, the concurrent use of drug therapy and physical prophylaxis before surgery is strongly recommended in hip fracture patients at high risk of VTE in our aging society.
DVT and PE-potential complications following THA-can be life-threatening, but fortunately, the reported prevalences of DVT and PE are low in Asians and Koreans because of relatively low obesity rates and serum lipid levels, and differences in ethnicity related genetic factors.
Considering complications of routine thromboprophylaxis (e.g., bleeding, hematoma, skin necrosis and infections), it would be more reasonable to use thromboprophylaxis depending on the individual needs of a patient (e.g., medical history and conditions), rather than following the guidelines for Western patients.
Anticoagulants for thromboprophylaxis cannot be easily used in many artificial joint patients who may experience complications due to routine use of thromboprophylaxis with anticoagulants, although not required, but only to avoid uncommon fatal PE.
Fortunately, the recommendations for VTE prophylaxis have been updated and the VTE prevention guidelines recommended by the Korea Hip Society are expected to serve as guidance for the appropriate treatment of Asian populations including Koreans.
Yu Seok Seo, MD, Soo Jae Yim, MD
Hip Pelvis 2012; 24(4): 279-287Fabio Mancino, MD, Andreas Fontalis, MD, MSc (Res), MRCS (Eng), Ahmed Magan, BM, BSc (Hons), MRCS, FRCS (Tra&Orth), Ricci Plastow, MBChB, FRCS (Eng), Fares S. Haddad, BSc, MD (Res), MCh (Orth), FRCS (Orth), FFSEM
Hip Pelvis 2024; 36(1): 26-36Sajid Ansari, MCh, Kshitij Gupta, MS, Tushar Gupta, MS, Balgovind S. Raja, MCh*, Pranav J., MBBS, Roop Bhushan Kalia, MS
Hip Pelvis 2024; 36(1): 12-25